Edition:
United Kingdom

Ocular Therapeutix Inc (OCUL.OQ)

OCUL.OQ on NASDAQ Stock Exchange Global Market

6.17USD
16 Aug 2018
Change (% chg)

$0.12 (+1.98%)
Prev Close
$6.05
Open
$6.16
Day's High
$6.25
Day's Low
$6.04
Volume
75,657
Avg. Vol
84,552
52-wk High
$8.26
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Ocular Therapeutix Reports Second Quarter 2018 Financial Results
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE.Q2 LOSS PER SHARE $0.37.Q2 EARNINGS PER SHARE VIEW $-0.38 -- THOMSON REUTERS I/B/E/S.OCULAR THERAPEUTIX - AS OF QUARTER-END, HAD $56.8 MILLION IN CASH AND CASH EQUIVALENTS VERSUS $62.9 MILLION AT END OF Q1.OCULAR THERAPEUTIX - BELIEVES EXISTING CASH AND CASH EQUIVALENTS WILL FUND OPERATING EXPENSES, DEBT SERVICE OBLIGATIONS, AND CAPEX INTO Q2 2019.  Full Article

Ocular Therapeutix Announces FDA Acceptance Of NDA Resubmission For Dextenza
Thursday, 19 Jul 2018 

July 19 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ ANNOUNCES FDA ACCEPTANCE OF NDA RESUBMISSION FOR DEXTENZA®.OCULAR - FDA CONSIDERS NDA RESUBMISSION AS CLASS 2 RESPONSE TO JULY 2017 CRL WITH PDUFA TARGET DATE OF DEC 28, 2018 FOR FDA'S DEXTENZA NDA REVIEW.  Full Article

Ocular Therapeutix Announces Proposed Public Offering Of Common Stock
Wednesday, 24 Jan 2018 

Jan 24 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.OCULAR THERAPEUTIX - TO USE PROCEEDS FROM OFFERING, EXISTING CASH AND EQUIVALENTS, TO FUND PLANNED RESUBMISSION OF NEW DRUG APPLICATION FOR DEXTENZA.OCULAR THERAPEUTIX - TO ALSO USE PROCEEDS TO FUND CLINICAL DEVELOPMENT OF OTX-TP, OTX-TIC AND OTX-TKI, ADDITIONAL PRECLINICAL, REGULATORY ACTIVITIES.  Full Article

Ocular Therapeutix Provides Legal Update
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Ocular Therapeutix Inc ::OCULAR THERAPEUTIX™ PROVIDES LEGAL UPDATE.OCULAR THERAPEUTIX INC - ON DEC. 21, CO WAS SERVED WITH A NEW DERIVATIVE COMPLAINT.OCULAR THERAPEUTIX - RECEIVED A SUBPOENA FROM SEC, DATED DEC 15, REQUESTING DOCUMENTS AND INFORMATION CONCERNING DEXTENZA 0.4 MG.  Full Article

Ocular Therapeutix posts Q3 loss per share $0.54
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Ocular Therapeutix Inc :Ocular Therapeutix reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.54.Q3 earnings per share view $-0.53 -- Thomson Reuters I/B/E/S.Ocular Therapeutix Inc - cash and cash equivalents at Sept 30, 2017 $51.2 million versus $32.9 million at Dec 31,2016‍​.Ocular Therapeutix - expects cash, cash equivalents to be enough to fund operating expenses, debt service obligations, capital expenditures into Q4 of 2018​.  Full Article

Ocular and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept
Thursday, 13 Oct 2016 

Ocular Therapeutix Inc : Ocular Therapeutix(tm) and Regeneron enter into strategic collaboration to develop sustained release formulation of aflibercept for the treatment of wet AMD and other serious retinal diseases .Ocular Therapeutix Inc - eligible to receive up to $305 million in milestone payments in addition to royalties on potential future net sales.  Full Article

BRIEF-Ocular Therapeutix Reports Q1 Loss Per Share $0.40

* OCULAR THERAPEUTIX™ REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS UPDATE